DK0891365T3 - Benzoxaziner til forstærkning af synaptiske responser - Google Patents

Benzoxaziner til forstærkning af synaptiske responser

Info

Publication number
DK0891365T3
DK0891365T3 DK97919965T DK97919965T DK0891365T3 DK 0891365 T3 DK0891365 T3 DK 0891365T3 DK 97919965 T DK97919965 T DK 97919965T DK 97919965 T DK97919965 T DK 97919965T DK 0891365 T3 DK0891365 T3 DK 0891365T3
Authority
DK
Denmark
Prior art keywords
compounds
subjects
ampa receptors
enhancing
synaptic responses
Prior art date
Application number
DK97919965T
Other languages
English (en)
Inventor
Gary A Rogers
Gary S Lynch
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0891365T3 publication Critical patent/DK0891365T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK97919965T 1996-04-03 1997-03-28 Benzoxaziner til forstærkning af synaptiske responser DK0891365T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/624,335 US5736543A (en) 1996-04-03 1996-04-03 Benzoxazines for enhancing synaptic response
PCT/US1997/005184 WO1997036907A1 (en) 1996-04-03 1997-03-28 Benzoxazines for enhancing synaptic response

Publications (1)

Publication Number Publication Date
DK0891365T3 true DK0891365T3 (da) 2003-02-10

Family

ID=24501596

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97919965T DK0891365T3 (da) 1996-04-03 1997-03-28 Benzoxaziner til forstærkning af synaptiske responser

Country Status (10)

Country Link
US (2) US5736543A (da)
EP (1) EP0891365B1 (da)
JP (1) JP3170294B2 (da)
AT (1) ATE226206T1 (da)
AU (1) AU708212B2 (da)
DE (1) DE69716414T2 (da)
DK (1) DK0891365T3 (da)
ES (1) ES2185932T3 (da)
NZ (1) NZ331992A (da)
WO (1) WO1997036907A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721936B2 (en) * 1996-04-03 2000-07-20 Regents Of The University Of California, The Benzoxazines for enhancing synaptic response
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
CA2306817A1 (en) * 1997-10-27 1999-05-06 Cortex Pharmaceuticals Inc. Treatment of schizophrenia with ampakines and neuroleptics
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6011991A (en) * 1998-12-07 2000-01-04 Technology Patents, Llc Communication system and method including brain wave analysis and/or use of brain activity
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
HUP0400196A3 (en) 2001-06-14 2007-05-02 Organon Nv (pyrido/thieno)[f]oxazepin-5-one derivatives, their use and pharmaceutical compositions containing them
PL371722A1 (en) * 2001-11-26 2005-06-27 Cortex Pharmaceuticals, Inc. Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
KR100974843B1 (ko) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
WO2004062616A2 (en) 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
AU2007342364A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
MY154877A (en) * 2007-01-03 2015-08-14 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2008118644A1 (en) * 2007-03-23 2008-10-02 The Regents Of The University Of California Treatment of female sexual dysfunction by compounds that positively modulate ampa-type glutamate receptors
EA200901546A1 (ru) 2007-05-17 2010-04-30 Кортекс Фармасеутикалс, Инк. Дизамещенные амиды для усиления глутаматергических синаптических ответов
BRPI0814149A2 (pt) 2007-08-10 2011-09-13 Cortex Pharma Inc composto, composição farmacêutica, métodos de tratamento e uso do composto
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
EP2948135B1 (en) 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
US20190112300A1 (en) 2016-03-29 2019-04-18 Arnold Stan Lippa Compositions And Methods For Treating Attention Deficit Disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257396A (en) * 1962-06-11 1966-06-21 Geigy Chem Corp Certain 1, 3-benzoxazinone derivatives
EP1156043B1 (en) * 1992-07-24 2003-11-12 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response

Also Published As

Publication number Publication date
JP3170294B2 (ja) 2001-05-28
AU2427497A (en) 1997-10-22
EP0891365A1 (en) 1999-01-20
DE69716414T2 (de) 2003-06-12
US5736543A (en) 1998-04-07
AU708212B2 (en) 1999-07-29
DE69716414D1 (de) 2002-11-21
WO1997036907A1 (en) 1997-10-09
ATE226206T1 (de) 2002-11-15
NZ331992A (en) 1999-02-25
EP0891365B1 (en) 2002-10-16
US5962447A (en) 1999-10-05
JP2000503664A (ja) 2000-03-28
ES2185932T3 (es) 2003-05-01

Similar Documents

Publication Publication Date Title
AU2427497A (en) Benzoxazines for enhancing synaptic response
PT839134E (pt) Benzoilpiperidinas/pirrolidinas para melhoramento da resposta sinaptica
DK1054673T3 (da) Benzoxazinforbindelser til forstærkelse af synaptisk reaktion
CA2138533A1 (en) Drugs that enhance synaptic responses mediated by ampa receptors
NO993768D0 (no) Benzofuranforbindelser med AMPA reseptor aktivitet
DE69833451D1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
PT1067935E (pt) Acilbenzoxazinas para melhorar resposta (s) sinaptica (s)
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов